Share Price and Basic Stock Data
Last Updated: January 10, 2026, 5:29 am
| PEG Ratio | -10.38 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Metropolis Healthcare Ltd operates in the Hospitals & Medical Services sector, with a current market capitalization of ₹10,330 Cr. The company’s share price stands at ₹1,988, reflecting a P/E ratio of 65.3, which is notably high compared to typical sector averages. Revenue trends indicate a fluctuating sales performance, with reported sales of ₹1,148 Cr for the fiscal year ending March 2023, down from ₹1,228 Cr in March 2022. However, the trailing twelve months (TTM) sales have rebounded to ₹1,483 Cr, indicating a recovery in demand. Quarterly sales also show a positive trend, with ₹308 Cr reported in September 2023, up from ₹277 Cr in June 2023. The sales growth trajectory appears promising, with expected sales of ₹1,331 Cr in March 2025, suggesting a strategic recovery post-pandemic. The company’s operational model and service offerings remain critical to its revenue generation, as healthcare services continue to gain importance in the Indian market.
Profitability and Efficiency Metrics
Metropolis Healthcare reported a net profit of ₹159 Cr, with a net profit margin of 10.93% for the fiscal year ending March 2025, which is lower than the 17.47% margin recorded in March 2022. Operating profit margin (OPM) also declined to 23.89% from 29.34% in March 2022, reflecting increasing operational costs and pressures on profitability. The return on equity (ROE) stood at 11.5%, while the return on capital employed (ROCE) was reported at 14.7%, both of which are considered moderate compared to industry standards. The company’s ability to manage expenses is highlighted by an interest coverage ratio (ICR) of 17.13x, indicating strong earnings relative to interest obligations. Additionally, the cash conversion cycle is notably efficient at -65 days, demonstrating effective management of working capital. Despite the challenges, the operational efficiency metrics suggest that Metropolis is well-positioned to improve profitability in the upcoming quarters.
Balance Sheet Strength and Financial Ratios
Metropolis Healthcare’s balance sheet reflects a robust equity position with reserves of ₹1,422 Cr and minimal borrowings of ₹201 Cr, indicating a low debt-to-equity ratio of 0.01. This financial structure supports the company’s stability and growth potential. The book value per share has increased to ₹256.94, providing a solid foundation for shareholder equity. The company’s liquidity ratios are also favorable, with a current ratio of 1.18 and a quick ratio of 1.01, suggesting adequate short-term financial stability. However, the enterprise value (EV) to net operating revenue stands at 6.06x, higher than typical sector averages, indicating potential overvaluation concerns. The price-to-book value (P/BV) ratio is reported at 6.08x, which may signal high investor expectations for future growth. Overall, while the balance sheet is strong, the high valuation ratios may require careful monitoring as the market evolves.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Metropolis Healthcare indicates a diverse base of investors, with promoters holding 48.89% of shares as of September 2025. Foreign Institutional Investors (FIIs) have reduced their stake to 12.52% from a high of 25.67% in March 2023, reflecting potential concerns about valuation or market conditions. Domestic Institutional Investors (DIIs), however, have increased their holdings to 33.10%, highlighting growing confidence among local institutional investors. The total number of shareholders stands at 47,846, which has decreased from previous quarters, indicating some consolidation in ownership. The public holding remains relatively low at 5.48%, suggesting that retail investor interest may be waning. This mixed sentiment in shareholding could impact stock performance, with institutional support being a critical factor for future price stability and growth.
Outlook, Risks, and Final Insight
Looking ahead, Metropolis Healthcare faces a dual-edged scenario of opportunities and risks. Strengths include a strong balance sheet with low leverage and an efficient cash conversion cycle, which positions the company well for future growth. However, risks such as declining profit margins and a reduction in FII participation could weigh on investor sentiment. Furthermore, the high P/E and P/BV ratios might indicate potential overvaluation, which could lead to volatility if earnings do not meet market expectations. The healthcare sector’s growth trajectory remains promising, but Metropolis must navigate operational efficiency and cost management to enhance profitability. In a scenario where operational challenges persist, the company could see continued pressure on margins, while a robust recovery in healthcare demand could bolster revenue and margins, leading to a more favorable valuation.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 48.6 Cr. | 145 | 187/120 | 9.91 | 117 | 2.41 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 23.1 Cr. | 22.0 | 33.8/15.5 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 10.2 Cr. | 9.90 | 20.5/7.08 | 114 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 111 Cr. | 59.2 | 98.7/55.2 | 24.5 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 20.1 Cr. | 3.72 | 6.94/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 26,020.14 Cr | 692.34 | 90.26 | 93.18 | 0.33% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 300 | 285 | 283 | 277 | 308 | 291 | 331 | 313 | 350 | 323 | 345 | 386 | 429 |
| Expenses | 221 | 215 | 212 | 214 | 234 | 226 | 251 | 235 | 260 | 251 | 283 | 296 | 321 |
| Operating Profit | 79 | 70 | 70 | 63 | 75 | 65 | 80 | 79 | 90 | 72 | 62 | 90 | 108 |
| OPM % | 26% | 25% | 25% | 23% | 24% | 22% | 24% | 25% | 26% | 22% | 18% | 23% | 25% |
| Other Income | 4 | 7 | 1 | 3 | 1 | 2 | 3 | 2 | 3 | 3 | 7 | 8 | 1 |
| Interest | 7 | 6 | 6 | 6 | 6 | 5 | 6 | 5 | 5 | 5 | 5 | 5 | 6 |
| Depreciation | 22 | 23 | 23 | 21 | 22 | 25 | 26 | 26 | 27 | 28 | 29 | 31 | 32 |
| Profit before tax | 55 | 48 | 42 | 39 | 48 | 37 | 51 | 51 | 61 | 42 | 36 | 61 | 71 |
| Tax % | 26% | 25% | 20% | 26% | 26% | 26% | 28% | 25% | 24% | 26% | 19% | 26% | 26% |
| Net Profit | 40 | 36 | 33 | 29 | 36 | 27 | 37 | 38 | 47 | 31 | 29 | 45 | 53 |
| EPS in Rs | 7.88 | 6.99 | 6.51 | 5.62 | 6.92 | 5.30 | 7.11 | 7.41 | 9.08 | 6.12 | 5.63 | 8.70 | 10.17 |
Last Updated: December 29, 2025, 11:34 pm
Below is a detailed analysis of the quarterly data for Metropolis Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 429.00 Cr.. The value appears strong and on an upward trend. It has increased from 386.00 Cr. (Jun 2025) to 429.00 Cr., marking an increase of 43.00 Cr..
- For Expenses, as of Sep 2025, the value is 321.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 296.00 Cr. (Jun 2025) to 321.00 Cr., marking an increase of 25.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 108.00 Cr.. The value appears strong and on an upward trend. It has increased from 90.00 Cr. (Jun 2025) to 108.00 Cr., marking an increase of 18.00 Cr..
- For OPM %, as of Sep 2025, the value is 25.00%. The value appears strong and on an upward trend. It has increased from 23.00% (Jun 2025) to 25.00%, marking an increase of 2.00%.
- For Other Income, as of Sep 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8.00 Cr. (Jun 2025) to 1.00 Cr., marking a decrease of 7.00 Cr..
- For Interest, as of Sep 2025, the value is 6.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.00 Cr. (Jun 2025) to 6.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 32.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 31.00 Cr. (Jun 2025) to 32.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 71.00 Cr.. The value appears strong and on an upward trend. It has increased from 61.00 Cr. (Jun 2025) to 71.00 Cr., marking an increase of 10.00 Cr..
- For Tax %, as of Sep 2025, the value is 26.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 26.00%.
- For Net Profit, as of Sep 2025, the value is 53.00 Cr.. The value appears strong and on an upward trend. It has increased from 45.00 Cr. (Jun 2025) to 53.00 Cr., marking an increase of 8.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 10.17. The value appears strong and on an upward trend. It has increased from 8.70 (Jun 2025) to 10.17, marking an increase of 1.47.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:59 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 388 | 456 | 475 | 545 | 647 | 761 | 856 | 998 | 1,228 | 1,148 | 1,208 | 1,331 | 1,483 |
| Expenses | 285 | 339 | 359 | 405 | 467 | 559 | 619 | 708 | 880 | 855 | 920 | 1,023 | 1,151 |
| Operating Profit | 104 | 117 | 116 | 140 | 181 | 203 | 237 | 290 | 348 | 293 | 288 | 308 | 332 |
| OPM % | 27% | 26% | 24% | 26% | 28% | 27% | 28% | 29% | 28% | 26% | 24% | 23% | 22% |
| Other Income | 10 | 7 | 29 | 39 | 6 | 8 | -17 | 12 | 34 | 15 | 9 | 15 | 18 |
| Interest | 3 | 2 | 2 | 2 | 4 | 4 | 13 | 12 | 25 | 32 | 28 | 24 | 20 |
| Depreciation | 16 | 21 | 17 | 17 | 19 | 20 | 39 | 46 | 63 | 89 | 94 | 109 | 120 |
| Profit before tax | 95 | 101 | 128 | 160 | 164 | 187 | 169 | 244 | 293 | 188 | 175 | 191 | 211 |
| Tax % | 34% | 33% | 36% | 33% | 32% | 34% | 24% | 25% | 27% | 24% | 26% | 24% | |
| Net Profit | 63 | 68 | 82 | 107 | 112 | 124 | 128 | 183 | 215 | 143 | 128 | 146 | 159 |
| EPS in Rs | 57.34 | 61.82 | 80.47 | 106.52 | 109.23 | 23.94 | 25.15 | 35.82 | 41.85 | 27.90 | 24.95 | 27.99 | 30.62 |
| Dividend Payout % | 2% | 0% | 100% | 49% | 0% | 55% | 32% | 22% | 19% | 29% | 16% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 7.94% | 20.59% | 30.49% | 4.67% | 10.71% | 3.23% | 42.97% | 17.49% | -33.49% | -10.49% | 14.06% |
| Change in YoY Net Profit Growth (%) | 0.00% | 12.65% | 9.90% | -25.81% | 6.04% | -7.49% | 39.74% | -25.48% | -50.97% | 23.00% | 24.55% |
Metropolis Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 9% |
| 3 Years: | 3% |
| TTM: | 13% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -1% |
| 3 Years: | -12% |
| TTM: | 11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 4% |
| 3 Years: | 17% |
| 1 Year: | 4% |
| Return on Equity | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 17% |
| 3 Years: | 13% |
| Last Year: | 12% |
Last Updated: Unknown
Balance Sheet
Last Updated: December 10, 2025, 3:05 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 292 | 352 | 269 | 314 | 405 | 408 | 513 | 696 | 876 | 978 | 1,086 | 1,321 | 1,422 |
| Borrowings | 20 | 14 | 5 | 1 | 1 | 18 | 67 | 112 | 379 | 266 | 197 | 204 | 201 |
| Other Liabilities | 69 | 87 | 107 | 188 | 110 | 113 | 160 | 181 | 256 | 240 | 254 | 324 | 359 |
| Total Liabilities | 391 | 462 | 391 | 512 | 526 | 550 | 750 | 1,000 | 1,521 | 1,495 | 1,547 | 1,859 | 1,993 |
| Fixed Assets | 149 | 153 | 142 | 202 | 207 | 213 | 296 | 343 | 1,059 | 1,121 | 1,177 | 1,447 | 1,573 |
| CWIP | 1 | 0 | 1 | 1 | 0 | 6 | 3 | 0 | 6 | 20 | 0 | 0 | 0 |
| Investments | 132 | 168 | 101 | 142 | 102 | 33 | 14 | 10 | 16 | 15 | 55 | 71 | 21 |
| Other Assets | 109 | 141 | 147 | 167 | 216 | 298 | 437 | 647 | 440 | 340 | 316 | 341 | 399 |
| Total Assets | 391 | 462 | 391 | 512 | 526 | 550 | 750 | 1,000 | 1,521 | 1,495 | 1,547 | 1,859 | 1,993 |
Below is a detailed analysis of the balance sheet data for Metropolis Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,422.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,321.00 Cr. (Mar 2025) to 1,422.00 Cr., marking an increase of 101.00 Cr..
- For Borrowings, as of Sep 2025, the value is 201.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 204.00 Cr. (Mar 2025) to 201.00 Cr., marking a decrease of 3.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 359.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 324.00 Cr. (Mar 2025) to 359.00 Cr., marking an increase of 35.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,993.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,859.00 Cr. (Mar 2025) to 1,993.00 Cr., marking an increase of 134.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,573.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,447.00 Cr. (Mar 2025) to 1,573.00 Cr., marking an increase of 126.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 21.00 Cr.. The value appears to be declining and may need further review. It has decreased from 71.00 Cr. (Mar 2025) to 21.00 Cr., marking a decrease of 50.00 Cr..
- For Other Assets, as of Sep 2025, the value is 399.00 Cr.. The value appears strong and on an upward trend. It has increased from 341.00 Cr. (Mar 2025) to 399.00 Cr., marking an increase of 58.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,993.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,859.00 Cr. (Mar 2025) to 1,993.00 Cr., marking an increase of 134.00 Cr..
Notably, the Reserves (1,422.00 Cr.) exceed the Borrowings (201.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 84.00 | 103.00 | 111.00 | 139.00 | 180.00 | 185.00 | 170.00 | 178.00 | -31.00 | 27.00 | 91.00 | 104.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 47 | 57 | 54 | 54 | 57 | 66 | 55 | 45 | 40 | 39 | 38 | 41 |
| Inventory Days | 47 | 52 | 46 | 38 | 53 | 55 | 44 | 59 | 68 | 64 | 58 | 65 |
| Days Payable | 75 | 92 | 96 | 97 | 88 | 90 | 152 | 160 | 136 | 136 | 150 | 171 |
| Cash Conversion Cycle | 19 | 17 | 3 | -5 | 21 | 30 | -54 | -56 | -29 | -33 | -53 | -65 |
| Working Capital Days | 22 | 32 | 8 | -27 | 28 | 33 | 2 | -9 | -26 | -22 | -16 | -18 |
| ROCE % | 28% | 34% | 46% | 43% | 43% | 40% | 36% | 29% | 17% | 16% | 15% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Focused Fund | 1,700,000 | 1.25 | 328.27 | N/A | N/A | N/A |
| HDFC Flexi Cap Fund | 1,625,000 | 0.33 | 313.79 | N/A | N/A | N/A |
| Kotak Small Cap Fund | 1,246,043 | 1.38 | 240.61 | N/A | N/A | N/A |
| Nippon India Small Cap Fund | 1,145,336 | 0.32 | 221.16 | 1,085,411 | 2025-12-08 00:54:44 | 5.52% |
| HDFC ELSS Tax Saver Fund | 800,000 | 0.9 | 154.48 | N/A | N/A | N/A |
| Canara Robeco Small Cap Fund | 719,004 | 1.06 | 138.84 | N/A | N/A | N/A |
| Franklin India Small Cap Fund | 715,459 | 1.02 | 138.16 | 790,459 | 2025-12-14 00:32:36 | -9.49% |
| Aditya Birla Sun Life Flexi Cap Fund | 700,000 | 0.54 | 135.17 | 506,015 | 2025-12-08 00:54:44 | 38.34% |
| Franklin India Opportunities Fund | 649,673 | 1.51 | 125.45 | N/A | N/A | N/A |
| HDFC Hybrid Equity Fund | 612,876 | 0.48 | 118.35 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 28.29 | 24.95 | 27.91 | 41.87 | 35.97 |
| Diluted EPS (Rs.) | 28.15 | 24.87 | 27.91 | 41.66 | 35.79 |
| Cash EPS (Rs.) | 49.07 | 43.52 | 45.42 | 54.31 | 44.86 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 256.94 | 213.98 | 193.46 | 173.56 | 138.52 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 256.94 | 213.98 | 193.46 | 173.56 | 138.52 |
| Revenue From Operations / Share (Rs.) | 256.99 | 235.76 | 224.21 | 240.04 | 195.24 |
| PBDIT / Share (Rs.) | 61.41 | 56.94 | 59.27 | 70.43 | 58.31 |
| PBIT / Share (Rs.) | 40.43 | 38.50 | 41.85 | 58.08 | 49.32 |
| PBT / Share (Rs.) | 36.84 | 34.10 | 36.61 | 57.33 | 47.80 |
| Net Profit / Share (Rs.) | 28.09 | 25.08 | 28.00 | 41.95 | 35.87 |
| NP After MI And SOA / Share (Rs.) | 27.99 | 24.95 | 27.90 | 41.86 | 35.82 |
| PBDIT Margin (%) | 23.89 | 24.15 | 26.43 | 29.34 | 29.86 |
| PBIT Margin (%) | 15.73 | 16.33 | 18.66 | 24.19 | 25.26 |
| PBT Margin (%) | 14.33 | 14.46 | 16.33 | 23.88 | 24.48 |
| Net Profit Margin (%) | 10.93 | 10.63 | 12.48 | 17.47 | 18.37 |
| NP After MI And SOA Margin (%) | 10.89 | 10.58 | 12.44 | 17.43 | 18.34 |
| Return on Networth / Equity (%) | 10.89 | 11.66 | 14.45 | 24.11 | 25.91 |
| Return on Capital Employeed (%) | 13.31 | 15.06 | 17.32 | 24.18 | 31.49 |
| Return On Assets (%) | 7.76 | 8.21 | 9.51 | 13.99 | 18.22 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.02 | 0.17 | 0.00 |
| Total Debt / Equity (X) | 0.01 | 0.00 | 0.07 | 0.29 | 0.00 |
| Asset Turnover Ratio (%) | 0.77 | 0.79 | 0.75 | 0.95 | 0.96 |
| Current Ratio (X) | 1.18 | 1.28 | 1.14 | 1.30 | 2.98 |
| Quick Ratio (X) | 1.01 | 1.13 | 0.97 | 1.13 | 2.78 |
| Inventory Turnover Ratio (X) | 30.77 | 29.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 16.03 | 28.67 | 19.11 | 22.33 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 9.21 | 17.65 | 14.75 | 17.85 |
| Earning Retention Ratio (%) | 0.00 | 83.97 | 71.33 | 80.89 | 77.67 |
| Cash Earning Retention Ratio (%) | 0.00 | 90.79 | 82.35 | 85.25 | 82.15 |
| Interest Coverage Ratio (X) | 17.13 | 12.94 | 11.32 | 18.26 | 38.30 |
| Interest Coverage Ratio (Post Tax) (X) | 8.83 | 6.70 | 6.35 | 11.07 | 24.56 |
| Enterprise Value (Cr.) | 8063.19 | 8775.73 | 6384.27 | 10513.81 | 11037.23 |
| EV / Net Operating Revenue (X) | 6.06 | 7.27 | 5.56 | 8.56 | 11.06 |
| EV / EBITDA (X) | 25.35 | 30.09 | 21.03 | 29.17 | 37.03 |
| MarketCap / Net Operating Revenue (X) | 6.08 | 7.32 | 5.57 | 8.48 | 11.48 |
| Retention Ratios (%) | 0.00 | 83.96 | 71.32 | 80.88 | 77.66 |
| Price / BV (X) | 6.08 | 8.07 | 6.47 | 11.73 | 16.21 |
| Price / Net Operating Revenue (X) | 6.08 | 7.32 | 5.57 | 8.48 | 11.48 |
| EarningsYield | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 |
After reviewing the key financial ratios for Metropolis Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 28.29. This value is within the healthy range. It has increased from 24.95 (Mar 24) to 28.29, marking an increase of 3.34.
- For Diluted EPS (Rs.), as of Mar 25, the value is 28.15. This value is within the healthy range. It has increased from 24.87 (Mar 24) to 28.15, marking an increase of 3.28.
- For Cash EPS (Rs.), as of Mar 25, the value is 49.07. This value is within the healthy range. It has increased from 43.52 (Mar 24) to 49.07, marking an increase of 5.55.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 256.94. It has increased from 213.98 (Mar 24) to 256.94, marking an increase of 42.96.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 256.94. It has increased from 213.98 (Mar 24) to 256.94, marking an increase of 42.96.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 256.99. It has increased from 235.76 (Mar 24) to 256.99, marking an increase of 21.23.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 61.41. This value is within the healthy range. It has increased from 56.94 (Mar 24) to 61.41, marking an increase of 4.47.
- For PBIT / Share (Rs.), as of Mar 25, the value is 40.43. This value is within the healthy range. It has increased from 38.50 (Mar 24) to 40.43, marking an increase of 1.93.
- For PBT / Share (Rs.), as of Mar 25, the value is 36.84. This value is within the healthy range. It has increased from 34.10 (Mar 24) to 36.84, marking an increase of 2.74.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 28.09. This value is within the healthy range. It has increased from 25.08 (Mar 24) to 28.09, marking an increase of 3.01.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 27.99. This value is within the healthy range. It has increased from 24.95 (Mar 24) to 27.99, marking an increase of 3.04.
- For PBDIT Margin (%), as of Mar 25, the value is 23.89. This value is within the healthy range. It has decreased from 24.15 (Mar 24) to 23.89, marking a decrease of 0.26.
- For PBIT Margin (%), as of Mar 25, the value is 15.73. This value is within the healthy range. It has decreased from 16.33 (Mar 24) to 15.73, marking a decrease of 0.60.
- For PBT Margin (%), as of Mar 25, the value is 14.33. This value is within the healthy range. It has decreased from 14.46 (Mar 24) to 14.33, marking a decrease of 0.13.
- For Net Profit Margin (%), as of Mar 25, the value is 10.93. This value exceeds the healthy maximum of 10. It has increased from 10.63 (Mar 24) to 10.93, marking an increase of 0.30.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 10.89. This value is within the healthy range. It has increased from 10.58 (Mar 24) to 10.89, marking an increase of 0.31.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.89. This value is below the healthy minimum of 15. It has decreased from 11.66 (Mar 24) to 10.89, marking a decrease of 0.77.
- For Return on Capital Employeed (%), as of Mar 25, the value is 13.31. This value is within the healthy range. It has decreased from 15.06 (Mar 24) to 13.31, marking a decrease of 1.75.
- For Return On Assets (%), as of Mar 25, the value is 7.76. This value is within the healthy range. It has decreased from 8.21 (Mar 24) to 7.76, marking a decrease of 0.45.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.77. It has decreased from 0.79 (Mar 24) to 0.77, marking a decrease of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 1.18. This value is below the healthy minimum of 1.5. It has decreased from 1.28 (Mar 24) to 1.18, marking a decrease of 0.10.
- For Quick Ratio (X), as of Mar 25, the value is 1.01. This value is within the healthy range. It has decreased from 1.13 (Mar 24) to 1.01, marking a decrease of 0.12.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 30.77. This value exceeds the healthy maximum of 8. It has increased from 29.00 (Mar 24) to 30.77, marking an increase of 1.77.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 16.03 (Mar 24) to 0.00, marking a decrease of 16.03.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 9.21 (Mar 24) to 0.00, marking a decrease of 9.21.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 83.97 (Mar 24) to 0.00, marking a decrease of 83.97.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 90.79 (Mar 24) to 0.00, marking a decrease of 90.79.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 17.13. This value is within the healthy range. It has increased from 12.94 (Mar 24) to 17.13, marking an increase of 4.19.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.83. This value is within the healthy range. It has increased from 6.70 (Mar 24) to 8.83, marking an increase of 2.13.
- For Enterprise Value (Cr.), as of Mar 25, the value is 8,063.19. It has decreased from 8,775.73 (Mar 24) to 8,063.19, marking a decrease of 712.54.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 6.06. This value exceeds the healthy maximum of 3. It has decreased from 7.27 (Mar 24) to 6.06, marking a decrease of 1.21.
- For EV / EBITDA (X), as of Mar 25, the value is 25.35. This value exceeds the healthy maximum of 15. It has decreased from 30.09 (Mar 24) to 25.35, marking a decrease of 4.74.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 6.08. This value exceeds the healthy maximum of 3. It has decreased from 7.32 (Mar 24) to 6.08, marking a decrease of 1.24.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 83.96 (Mar 24) to 0.00, marking a decrease of 83.96.
- For Price / BV (X), as of Mar 25, the value is 6.08. This value exceeds the healthy maximum of 3. It has decreased from 8.07 (Mar 24) to 6.08, marking a decrease of 1.99.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 6.08. This value exceeds the healthy maximum of 3. It has decreased from 7.32 (Mar 24) to 6.08, marking a decrease of 1.24.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Metropolis Healthcare Ltd:
- Net Profit Margin: 10.93%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 13.31% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.89% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 8.83
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.01
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 62.9 (Industry average Stock P/E: 90.26)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 10.93%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | 4th Floor, East Wing, Mumbai Maharashtra 400030 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mrs. Ameera Sushil Shah | Exe.Chairman & W T D |
| Mr. Hemant Sachdev | Non Exe.Non Ind.Director |
| Dr. Aparna Rajadhyaksha | Non Exe.Non Ind.Director |
| Dr. Sushil Kanubhai Shah | Non Executive Director |
| Mr. Sanjay Bhatnagar | Independent Director |
| Mr. Subramanian Ranganathan | Independent Director |
| Ms. Purvi Sheth | Independent Director |
| Mr. Vivek Gambhir | Independent Director |
FAQ
What is the intrinsic value of Metropolis Healthcare Ltd?
Metropolis Healthcare Ltd's intrinsic value (as of 10 January 2026) is ₹1600.51 which is 16.64% lower the current market price of ₹1,920.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹9,952 Cr. market cap, FY2025-2026 high/low of ₹2,263/1,315, reserves of ₹1,422 Cr, and liabilities of ₹1,993 Cr.
What is the Market Cap of Metropolis Healthcare Ltd?
The Market Cap of Metropolis Healthcare Ltd is 9,952 Cr..
What is the current Stock Price of Metropolis Healthcare Ltd as on 10 January 2026?
The current stock price of Metropolis Healthcare Ltd as on 10 January 2026 is ₹1,920.
What is the High / Low of Metropolis Healthcare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Metropolis Healthcare Ltd stocks is ₹2,263/1,315.
What is the Stock P/E of Metropolis Healthcare Ltd?
The Stock P/E of Metropolis Healthcare Ltd is 62.9.
What is the Book Value of Metropolis Healthcare Ltd?
The Book Value of Metropolis Healthcare Ltd is 276.
What is the Dividend Yield of Metropolis Healthcare Ltd?
The Dividend Yield of Metropolis Healthcare Ltd is 0.21 %.
What is the ROCE of Metropolis Healthcare Ltd?
The ROCE of Metropolis Healthcare Ltd is 14.7 %.
What is the ROE of Metropolis Healthcare Ltd?
The ROE of Metropolis Healthcare Ltd is 11.5 %.
What is the Face Value of Metropolis Healthcare Ltd?
The Face Value of Metropolis Healthcare Ltd is 2.00.